Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Linezolid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 1.00 |
| ▸ | MAOA | P21397 | 7/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | SDHA | P31040 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CALML3 | P27482 | 1/20 | 1.00 |
| ▸ | F10 | P00742 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linezolid SCHEMBL374752 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL30638355 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL5524444 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL1561095 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL30226927 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2222512 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL5027 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2280731 | 0.99 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2279924 | 0.99 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL3904534 | 0.99 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188550-A1 | METHODS AND COMPOSITIONS FOR DRUG RESISTANCE SCREENING | Quadram Institute Bioscience (GB) | 2025-06-12 | — | — | US | claimed |
| CN-119780014-A | Method for detecting levofloxacin in wastewater by ultraviolet dual-wavelength | 中国科学院大连化学物理研究所 | 2025-04-08 | — | — | CN | claimed |
| EP-4490326-A1 | METHODS AND COMPOSITIONS FOR DRUG RESISTANCE SCREENING | Quadram Institute Bioscience (GB) | 2025-01-15 | — | — | EP | claimed |
| WO-2023170395-A9 | METHODS AND COMPOSITIONS FOR DRUG RESISTANCE SCREENING | Quadram Institute Bioscience (GB) | 2024-10-10 | — | — | WO | claimed |
| WO-2024136591-A1 | IDENTIFICATION AND RESISTANCE DIAGNOSIS OF MYCOBACTERIUM TUBERCULOSIS AND NONTUBERCULOUS MYCOBACTERIAL INFECTION USING NEXT-GENERATION SEQUENCING | 가톨릭대학교 산학협력단 | 2024-06-27 | — | — | WO | claimed |
| WO-2023227817-A1 | NANOPARTICLES FOR USE IN THE TREATMENT OF INFECTIONS CAUSED BY BIOFILMS | UNIVERSITAT POLITÈCNICA DE VALÈNCIA (ES) | 2023-11-30 | — | — | WO | claimed |
| WO-2023170395-A1 | METHODS AND COMPOSITIONS FOR DRUG RESISTANCE SCREENING | Quadram Institute Bioscience (GB) | 2023-09-14 | — | — | WO | claimed |
| US-20230137543-A1 | BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS | NESTEC S.A. (CH) | 2023-05-04 | — | — | US | claimed |
| EP-4076561-A1 | CATHETER DEVICE FOR RELEASING PHARMACEUTICALLY ACTIVE COMPOUNDS OVER AN EXTENDED PERIOD | Cirlo GmbH (DE) | 2022-10-26 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-4746883-A1 | COMBINATION PRODUCTS OF AT LEAST THREE ANTIBIOTICS COMPRISING BEDAQUILINE, PRETOMANID OR DELAMANID, AND A CYTOCHROME BC1 INHIBITOR, AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | Janssen Pharmaceutica NV (BE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026086794-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2026-04-30 | — | — | WO | disclosed |
| US-20260083674-A1 | OXAZOLIDINONE LIPOSOME COMPOSITIONS | AKAGERA MEDICINES, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4709739-A1 | ANTI-BACTERIAL PEPTIDES | Agency for Science, Technology and Research (SG) | 2026-03-18 | — | — | EP | disclosed |
| US-12570647-B2 | Amino benzothiazole compounds for treatment of antibiotic resistant bacteria | SAINT LOUIS UNIVERSITY (US) | 2026-03-10 | — | — | US | disclosed |
| US-20220042066-A1 | SYSTEMS AND METHODS FOR MICROCOLONY GROWTH AND MICROBIAL CELL CHARACTERIZATION | SHEMRON HOLDINGS INC. (CA) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| CN-113995726-A | Linezolid II crystal form tablet and preparation method thereof | 深圳万乐药业有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113975274-A | Cyclofused thiazoline 2-pyridones, method for the production thereof and use thereof for treating and/or preventing tuberculosis | 快尔生物技术公司 | 2022-01-28 | — | — | CN | disclosed |
| US-6297242-B1 | ACTIVE AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS, VANCOMYCIN-RESISTANT ENTEROCOCCI AND PENICILLIN- AND CEPHALOSPORIN-RESISTANT STREPTOCOCCUS PNEUMONIAE. | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570647-B2 | Amino benzothiazole compounds for treatment of antibiotic resistant bacteria | BCAT1, BCAT2, IL4I1 | MAOB 2279/4885MAOA 3161/4885PTGS1 1102/4885 |
| US-20260083674-A1 | OXAZOLIDINONE LIPOSOME COMPOSITIONS | TBCD, SLK, PLA2G2C | MAOB 3246/4885MAOA 3350/4885PTGS1 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.